New findings show programmable biomaterials can be delivered using needle injection to induce an immune response and fight deadly diseases
One of the reasons cancer is so deadly is that it can evade attack from the body’s immune system, which allows tumors to flourish and spread. Scientists can try to induce the immune system, known as immunotherapy, to go into attack mode to fight cancer and to build long lasting immune resistance to cancer cells. Now, researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard’s School of Engineering and Applied Sciences (SEAS) show a non–surgical injection of programmable biomaterial that spontaneously assembles in vivo into a 3D structure could fight and even help prevent cancer and also infectious disease such as HIV. Their findings are reported in Nature Biotechnology.
“We can create 3D structures using minimally–invasive delivery to enrich and activate a host’s immune cells to target and attack harmful cells in vivo,” said the study’s senior author David Mooney, Ph.D., who is a Wyss Institute Core Faculty member and the Robert P. Pinkas Professor of Bioengineering at Harvard SEAS.
Tiny biodegradable rod–like structures made from silica, known as mesoporous silica rods (MSRs), can be loaded with biological and chemical drug components and then delivered by needle just underneath the skin. The rods spontaneously assemble at the vaccination site to form a three–dimensional scaffold, like pouring a box of matchsticks into a pile on a table. The porous spaces in the stack of MSRs are large enough to recruit and fill up with dendritic cells, which are “surveillance” cells that monitor the body and trigger an immune response when a harmful presence is detected.
“Nano–sized mesoporous silica particles have already been established as useful for manipulating individual cells from the inside, but this is the first time that larger particles, in the micron–sized range, are used to create a 3D in vivo scaffold that can recruit and attract tens of millions of immune cells,” said co-lead author Jaeyun Kim, Ph.D., an Assistant Professor of Chemical Engineering at Sungkyunkwan University and a former Wyss Institute Postdoctoral Fellow.
Synthesized in the lab, the MSRs are built with small holes, known as nanopores, inside. The nanopores can be filled with specific cytokines, oligonucleotides, large protein antigens, or any variety of drugs of interest to allow a vast number of possible combinations to treat a range of infections.
“Although right now we are focusing on developing a cancer vaccine, in the future we could be able to manipulate which type of dendritic cells or other types of immune cells are recruited to the 3D scaffold by using different kinds of cytokines released from the MSRs,” said co-lead author Aileen Li, a graduate student pursuing her Ph.D. in bioengineering at Harvard SEAS. “By tuning the surface properties and pore size of the MSRs, and therefore controlling the introduction and release of various proteins and drugs, we can manipulate the immune system to treat multiple diseases.”
The Latest on: Injectable 3D vaccines
[google_news title=”” keyword=”Injectable 3D vaccines” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Injectable 3D vaccines
- World-First mRNA Vaccine For Skin Cancer Commences Landmark Phase 3 Trialon April 26, 2024 at 7:02 am
A UK man has become one of the first to receive an experimental mRNA vaccine designed to prevent recurrence of melanoma skin cancer. Steve Young, a 52-year-old musician, had a stage II melanoma ...
- Large Injection Site Reactions After a Second Dose of Varicella Vaccineon April 24, 2024 at 5:00 pm
and erythema at the injection site 24 hours after receiving a second dose of monovalent varicella vaccine. During this same time period, the clinic administered 143 doses of MMRV vaccine and 729 ...
- VBIV VBI Vaccines Inc.on April 23, 2024 at 8:59 am
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV ...
- Vaccines Newson April 21, 2024 at 5:00 pm
Mar. 12, 2024 — Researchers have highlighted the importance of continued surveillance of emerging SARS-CoV-2 variants and vaccine performance as the virus continues to ... Optimizing Boosters ...
- COVID-19 vaccines: Get the factson April 17, 2024 at 5:45 am
In some people, COVID-19 vaccines can lead to heart complications called myocarditis and pericarditis. Myocarditis is the swelling, also called inflammation, of the heart muscle. Pericarditis is the ...
- Toward A Universal Covid Vaccineon April 10, 2024 at 9:54 am
Over time, the virus develops a series of mutations in the Spike protein and other genes that aid in immune evasion, resulting in a new variant and reduced efficacy for the latest vaccine. The need ...
- Does Pet Insurance Cover Vaccinations?on April 9, 2024 at 5:00 pm
For an additional monthly fee, you can add routine care coverage to your base policy to help pay for your pet’s wellness care, including vaccinations. Pets may need other injections, such as ...
- Must mRNA be cloaked in a lipid coat to serve as a vaccine?on April 2, 2024 at 4:59 pm
Schematic diagram illustrating jet injection of a "Naked mRNA" vaccine. (Image: Satoshi Uchida) During the COVID-19 pandemic, mRNA vaccines have proven to be highly effective, with billions of doses ...
- Cancer vaccineson March 26, 2024 at 5:00 pm
A phase I clinical trial of an adjuvant personalized mRNA neoantigen vaccine, autogene cevumeran, in patients with pancreatic ductal carcinoma demonstrates that the vaccine can induce T cell ...
- Large Injection Site Reactions After a Second Dose of Varicella Vaccineon March 22, 2024 at 5:00 pm
A 10-year-old boy presented to the clinic with a chief complaint of a reaction on his leg 2 days after receiving a single subcutaneous dose of varicella vaccine in the left thigh (different ...
via Bing News